Myriad Genetics, Inc. (MYGN) 10-Year Financial Performance & Capital Metrics

MYGN • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingHereditary & Pharmacogenomic Testing

AboutMyriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.Show more

Revenue $838M +11.2%
EBITDA -$62M +68.1%
Net Income -$127M +51.7%
EPS (Diluted) -1.41 +55.7%
Gross Margin 69.89% +1.8%
EBITDA Margin -7.44% +71.3%
Operating Margin -14.74% +56.9%
Net Margin -15.2% +56.5%
ROE -17.15% +45.6%
ROIC -12.01% +44.7%
Debt/Equity 0.20 +3.0%
Interest Coverage -44.11 +50.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.8x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.48%

5Y5.58%

3Y6.64%

TTM3.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-154.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM-136.52%

ROCE

10Y Avg-5.8%

5Y Avg-16.32%

3Y Avg-17.11%

Latest-13.32%

Peer Comparison

Hereditary & Pharmacogenomic Testing

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PREPrenetics Global Limited	226.73M	14.87	-4.09	40.83%	-93.53%	-33.01%		0.03
MYGNMyriad Genetics, Inc.	563.01M	6.04	-4.28	11.21%	-47.45%	-101.83%		0.20

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	753.8M	771.4M	772.6M	851.1M	638.6M	557M	690.6M	678.4M	753.2M	837.6M
Revenue Growth %	0.04%	0.02%	0%	0.1%	-0.25%	-0.13%	0.24%	-0.02%	0.11%	0.11%
Cost of Goods Sold+	157.3M	171.2M	177.2M	201M	186.1M	178.2M	197.6M	202M	236.2M	252.2M
COGS % of Revenue	0.21%	0.22%	0.23%	0.24%	0.29%	0.32%	0.29%	0.3%	0.31%	0.3%
Gross Profit+	596.5M	600.2M	595.4M	650.1M	452.5M	378.8M	493M	476.4M	517M	585.4M
Gross Margin %	0.79%	0.78%	0.77%	0.76%	0.71%	0.68%	0.71%	0.7%	0.69%	0.7%
Gross Profit Growth %	0.04%	0.01%	-0.01%	0.09%	-0.3%	-0.16%	0.3%	-0.03%	0.09%	0.13%
Operating Expenses+	429.7M	550.8M	537.9M	642.5M	684.2M	653.3M	683.5M	617M	774.4M	708.9M
OpEx % of Revenue	0.57%	0.71%	0.7%	0.75%	1.07%	1.17%	0.99%	0.91%	1.03%	0.85%
Selling, General & Admin	359.1M	476.4M	467.1M	556.6M	507.3M	500.7M	537.8M	514.7M	572.9M	560M
SG&A % of Revenue	0.48%	0.62%	0.6%	0.65%	0.79%	0.9%	0.78%	0.76%	0.76%	0.67%
Research & Development	70.6M	74.4M	70.8M	85.9M	77.2M	80.9M	81.9M	85.4M	88.7M	113.4M
R&D % of Revenue	0.09%	0.1%	0.09%	0.1%	0.12%	0.15%	0.12%	0.13%	0.12%	0.14%
Other Operating Expenses	1.2M	-2.5M	-400K	0	99.7M	0	63.8M	16.9M	112.8M	35.5M
Operating Income+	166.8M	49.4M	118.7M	7.6M	-231.7M	-194.8M	-190.5M	-140.6M	-257.4M	-123.5M
Operating Margin %	0.22%	0.06%	0.15%	0.01%	-0.36%	-0.35%	-0.28%	-0.21%	-0.34%	-0.15%
Operating Income Growth %	0.24%	-0.7%	1.4%	-0.94%	-31.49%	0.16%	0.02%	0.26%	-0.83%	0.52%
EBITDA+	193.5M	97.7M	173.1M	80.6M	-159.7M	-123.4M	-127.7M	-87.9M	-195.5M	-62.3M
EBITDA Margin %	0.26%	0.13%	0.22%	0.09%	-0.25%	-0.22%	-0.18%	-0.13%	-0.26%	-0.07%
EBITDA Growth %	0.22%	-0.5%	0.77%	-0.53%	-2.98%	0.23%	-0.03%	0.31%	-1.22%	0.68%
D&A (Non-Cash Add-back)	26.7M	48.3M	54.4M	73M	72M	71.4M	62.8M	52.7M	61.9M	61.2M
EBIT	166.8M	0	0	12M	-212.5M	-194.8M	-50.5M	-137.4M	-259.3M	-120.7M
Net Interest Income+	600K	-4.8M	-1.4M	-8.8M	-7.8M	9.2M	-5.9M	-600K	-400K	-1.1M
Interest Income	900K	1.2M	1.8M	3.2M	3M	9.2M	700K	2.6M	2.5M	1.7M
Interest Expense	300K	6M	3.2M	12M	10.8M	0	6.6M	3.2M	2.9M	2.8M
Other Income/Expense	1.2M	-1.7M	60.8M	-7.6M	8.4M	-88.9M	133.4M	0	-4.8M	0
Pretax Income+	168.9M	42.9M	116.9M	0	-223.3M	-283.7M	-57.1M	-140.6M	-262.2M	-123.5M
Pretax Margin %	0.22%	0.06%	0.15%	-	-0.35%	-0.51%	-0.08%	-0.21%	-0.35%	-0.15%
Income Tax+	43.6M	21.3M	-13.9M	-4.4M	-23.7M	59.9M	-29.9M	-28.6M	1.1M	3.8M
Effective Tax Rate %	0.74%	0.51%	1.12%	-	0.89%	0.79%	0.48%	0.8%	1%	1.03%
Net Income+	125.3M	21.8M	131M	4.6M	-199.5M	-223.7M	-27.2M	-112M	-263.3M	-127.3M
Net Margin %	0.17%	0.03%	0.17%	0.01%	-0.31%	-0.4%	-0.04%	-0.17%	-0.35%	-0.15%
Net Income Growth %	0.56%	-0.83%	5.01%	-0.96%	-44.37%	-0.12%	0.88%	-3.12%	-1.35%	0.52%
Net Income (Continuing)	125.3M	-	-	4.4M	-199.6M	-	-27.2M	-112M	-263.3M	-127.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	-400K	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.71	0.32	1.82	0.06	-2.69	-2.99	-0.35	-1.39	-3.18	-1.41
EPS Growth %	0.58%	-0.81%	4.69%	-0.97%	-45.36%	-0.11%	0.88%	-2.97%	-1.29%	0.56%
EPS (Basic)	1.79	0.32	1.89	0.06	-2.69	-2.99	-0.35	-1.39	-3.18	-1.41
Diluted Shares Outstanding	73.4M	68.8M	72M	76M	74.3M	74.78M	78M	80.6M	82.8M	90.6M
Basic Shares Outstanding	70M	68.3M	69.4M	73.5M	74.3M	74.7M	77.71M	80.58M	82.8M	90.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	314.5M	317.1M	326.4M	348.6M	348.6M	389.4M	484.8M	274.6M	313.6M	298M
Cash & Short-Term Investments	159M	150.7M	180.6M	136.9M	136.9M	150.7M	339.8M	114.9M	140.9M	102.4M
Cash Only	68.5M	102.4M	110.9M	93.2M	93.2M	117M	258.4M	56.9M	132.1M	102.4M
Short-Term Investments	90.5M	48.3M	69.7M	43.7M	43.7M	33.7M	81.4M	58M	8.8M	0
Accounts Receivable	95M	111.3M	102.1M	138.6M	138.6M	89.5M	91.3M	101.6M	114.3M	121.2M
Days Sales Outstanding	46	52.66	48.24	59.44	79.22	58.65	48.25	54.66	55.39	52.82
Inventory	38.3M	42.2M	34.3M	31.4M	31.4M	27.1M	15.3M	20.1M	22M	27.5M
Days Inventory Outstanding	88.87	89.97	70.65	57.02	61.59	55.51	28.26	36.32	34	39.8
Other Current Assets	22.2M	12.9M	9.4M	46.4M	41.7M	0	38.4M	20.4M	19.4M	30.5M
Total Non-Current Assets+	566M	907.3M	847.7M	1.21B	1.21B	1.03B	835.9M	924.1M	832.9M	729.6M
Property, Plant & Equipment	58.3M	51.1M	43.2M	57.3M	57.3M	100.4M	125.3M	187.3M	180.6M	172.4M
Fixed Asset Turnover	12.93x	15.10x	17.88x	14.85x	11.14x	5.55x	5.51x	3.62x	4.17x	4.86x
Goodwill	195.3M	316.1M	318.6M	417.2M	417.2M	329.2M	239.2M	286.8M	287.4M	286.3M
Intangible Assets	227.5M	491.6M	455.2M	684.7M	684.7M	578.8M	404.1M	379.7M	349.5M	262.4M
Long-Term Investments	79.9M	48.5M	30.7M	54.9M	54.9M	21M	59M	54.8M	0	0
Other Non-Current Assets	5M	0	0	-1.21B	0	0	8.3M	15.5M	15.4M	8.5M
Total Assets+	880.5M	1.22B	1.17B	1.56B	1.56B	1.42B	1.32B	1.2B	1.15B	1.03B
Asset Turnover	0.86x	0.63x	0.66x	0.54x	0.41x	0.39x	0.52x	0.57x	0.66x	0.82x
Asset Growth %	0.15%	0.39%	-0.04%	0.33%	0%	-0.09%	-0.07%	-0.09%	-0.04%	-0.1%
Total Current Liabilities+	72.3M	217.5M	102.2M	117.8M	117.8M	145.9M	204.3M	137.2M	155.9M	164.1M
Accounts Payable	21.1M	22M	26M	33.3M	33.3M	20.5M	29.6M	28.8M	25.8M	32.3M
Days Payables Outstanding	48.96	46.9	53.56	60.47	65.31	41.99	54.68	52.04	39.87	46.75
Short-Term Debt	0	65.6M	68.3M	78.9M	78.9M	0	13M	14.1M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	1000K	600K	0	0
Other Current Liabilities	49.5M	127.3M	5.3M	82.3M	-29.9M	49.7M	126.9M	64.9M	38.2M	64.9M
Current Ratio	4.35x	1.46x	3.19x	2.96x	2.96x	2.67x	2.37x	2.00x	2.01x	1.82x
Quick Ratio	3.82x	1.26x	2.86x	2.69x	2.69x	2.48x	2.30x	1.85x	1.87x	1.65x
Cash Conversion Cycle	85.91	95.73	65.33	55.99	75.49	72.17	21.84	38.94	49.52	45.87
Total Non-Current Liabilities+	60.1M	229.1M	107M	356M	356M	391.9M	148.6M	175.7M	207.4M	162.4M
Long-Term Debt	0	99.1M	9.3M	233.5M	233.5M	224.8M	79.3M	130.9M	38.5M	39.6M
Capital Lease Obligations	0	0	0	0	0	50.6M	0	0	97.4M	87.9M
Deferred Tax Liabilities	17.9M	84.4M	57.3M	82.6M	82.6M	0	35.8M	3.5M	0	0
Other Non-Current Liabilities	42.2M	45.6M	40.4M	39.9M	39.9M	116.5M	33.5M	41.3M	71.5M	34.9M
Total Liabilities	132.4M	446.6M	209.2M	473.8M	473.8M	537.8M	352.9M	312.9M	363.3M	326.5M
Total Debt+	0	99.1M	9.3M	233.5M	233.5M	289M	92.3M	145M	152.1M	140.3M
Net Debt	-68.5M	-3.3M	-101.6M	140.3M	140.3M	172M	-166.1M	88.1M	20M	37.9M
Debt / Equity	-	0.13x	0.01x	0.21x	0.21x	0.33x	0.10x	0.16x	0.19x	0.20x
Debt / EBITDA	-	1.01x	0.05x	2.90x	-	-	-	-	-	-
Net Debt / EBITDA	-0.35x	-0.03x	-0.59x	1.74x	-	-	-	-	-	-
Interest Coverage	556.00x	8.23x	37.09x	0.63x	-21.45x	-	-28.86x	-43.94x	-88.76x	-44.11x
Total Equity+	748.1M	777.8M	964.9M	1.09B	1.09B	881M	967.8M	885.8M	783.2M	701.1M
Equity Growth %	0.13%	0.04%	0.24%	0.13%	0%	-0.19%	0.1%	-0.08%	-0.12%	-0.1%
Book Value per Share	10.19	11.31	13.40	14.33	14.66	11.78	12.41	10.99	9.46	7.74
Total Shareholders' Equity	748.1M	778.2M	964.9M	1.09B	1.09B	881M	967.8M	885.8M	783.2M	701.1M
Common Stock	700K	700K	700K	700K	700K	800K	800K	800K	900K	900K
Retained Earnings	-73.2M	-68.4M	52.8M	25.6M	25.6M	-227M	-254.2M	-366.2M	-629.5M	-756.8M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-9.5M	-5.5M	-4M	-5.4M	-5.4M	-2.3M	-5.1M	-8.9M	-3.7M	-800K
Minority Interest	0	-400K	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	166.3M	106.2M	115.9M	83.7M	60.7M	-26.9M	18.6M	-106.3M	-110.9M	-8.7M
Operating CF Margin %	0.22%	0.14%	0.15%	0.1%	0.1%	-0.05%	0.03%	-0.16%	-0.15%	-0.01%
Operating CF Growth %	0.18%	-0.36%	0.09%	-0.28%	-0.27%	-1.44%	1.69%	-6.72%	-0.04%	0.92%
Net Income	117.2M	17.4M	133.3M	4.6M	-199.5M	-223.7M	-27.2M	-112M	-263.3M	-127.3M
Depreciation & Amortization	26.8M	48.3M	54.4M	73M	72M	71.4M	62.8M	52.7M	61.9M	61.2M
Stock-Based Compensation	31.6M	29.9M	27.1M	33.5M	25.2M	24.3M	36.3M	38.1M	40.7M	49.8M
Deferred Taxes	10.8M	2M	-23.8M	13.1M	-54.1M	-54.5M	-34.7M	-31.9M	-600K	-300K
Other Non-Cash Items	32.4M	3M	-83.6M	-1.1M	99.2M	70.9M	-139.4M	30.3M	23.4M	62.3M
Working Capital Changes	-52.5M	5.6M	8.5M	-39.4M	117.9M	30.2M	120.8M	-83.5M	27M	-54.4M
Change in Receivables	-26.8M	-3.5M	-8M	-18.2M	64M	28.9M	-8.8M	7.7M	3.8M	-8.7M
Change in Inventory	-14.6M	-1.2M	7.9M	8M	1.6M	1.3M	1.6M	-2.9M	-1.8M	-6.2M
Change in Payables	0	-3M	4M	1.1M	-10.7M	0	9.2M	-3.5M	-3.7M	4.7M
Cash from Investing+	-91.4M	-146.3M	-11.6M	-286.4M	19.3M	61.6M	274.4M	-77.5M	31.9M	-11.9M
Capital Expenditures	-5M	-6.1M	-8.4M	-8.6M	-10.2M	-13.2M	-18M	-45.3M	-73.3M	-29.7M
CapEx % of Revenue	0.01%	0.01%	0.01%	0.01%	0.02%	0.02%	0.03%	0.07%	0.1%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	74.8M	0	0	0	0
Cash from Financing+	-68.3M	71.8M	-95M	182.3M	-10M	-1M	-150.6M	-8M	152.9M	-7.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	94.3M	5.4M	-5M	7.3M	-1.4M	11.5M	75.8M	-8M	-4.5M	-7.5M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	161.3M	100.1M	107.5M	75.1M	50.5M	-40.1M	600K	-151.6M	-184.2M	-38.4M
FCF Margin %	0.21%	0.13%	0.14%	0.09%	0.08%	-0.07%	0%	-0.22%	-0.24%	-0.05%
FCF Growth %	0.38%	-0.38%	0.07%	-0.3%	-0.33%	-1.79%	1.01%	-253.67%	-0.22%	0.79%
FCF per Share	2.20	1.45	1.49	0.99	0.68	-0.54	0.01	-1.88	-2.22	-0.42
FCF Conversion (FCF/Net Income)	1.33x	4.87x	0.88x	18.20x	-0.30x	0.12x	-0.68x	0.95x	0.42x	0.07x
Interest Paid	300K	5.6M	3M	11.6M	9.5M	-	4.4M	-	1.4M	1.9M
Taxes Paid	32M	12.3M	11.7M	6.5M	1M	-	4.6M	1.8M	1.9M	2.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	17.77%	2.86%	15.03%	0.45%	-18.32%	-22.71%	-2.94%	-12.08%	-31.55%	-17.15%
Return on Invested Capital (ROIC)	19.58%	5.1%	10.87%	0.54%	-14.14%	-12.8%	-15.41%	-11.88%	-21.73%	-12.01%
Gross Margin	79.13%	77.81%	77.06%	76.38%	70.86%	68.01%	71.39%	70.22%	68.64%	69.89%
Net Margin	16.62%	2.83%	16.96%	0.54%	-31.24%	-40.16%	-3.94%	-16.51%	-34.96%	-15.2%
Debt / Equity	-	0.13x	0.01x	0.21x	0.21x	0.33x	0.10x	0.16x	0.19x	0.20x
Interest Coverage	556.00x	8.23x	37.09x	0.63x	-21.45x	-	-28.86x	-43.94x	-88.76x	-44.11x
FCF Conversion	1.33x	4.87x	0.88x	18.20x	-0.30x	0.12x	-0.68x	0.95x	0.42x	0.07x
Revenue Growth	4.25%	2.33%	0.16%	10.16%	-24.97%	-12.78%	23.99%	-1.77%	11.03%	11.21%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2021	2022	2023	2024
Testing Revenue	-	-	-	-	-	-	-	-	753.2M	-
Testing Revenue Growth	-	-	-	-	-	-	-	-	-	-
Molecular Diagnostic Testing	-	-	-	719.3M	789.4M	586.9M	-	-	-	-
Molecular Diagnostic Testing Growth	-	-	-	-	9.75%	-25.65%	-	-	-	-
Molecular Diagnostic Hereditary Cancer Testing	-	-	-	-	479.7M	347.4M	-	-	-	-
Molecular Diagnostic Hereditary Cancer Testing Growth	-	-	-	-	-	-27.58%	-	-	-	-
Molecular Diagnostic Prenatal Testing	-	-	-	-	104.9M	76.7M	-	-	-	-
Molecular Diagnostic Prenatal Testing Growth	-	-	-	-	-	-26.88%	-	-	-	-
Molecular Diagnostic Genesight Testing	-	-	-	-	112.6M	74.1M	-	-	-	-
Molecular Diagnostic Genesight Testing Growth	-	-	-	-	-	-34.19%	-	-	-	-
Pharmaceutical And Clinical Services	-	-	-	53.3M	61.7M	51.7M	-	-	-	-
Pharmaceutical And Clinical Services Growth	-	-	-	-	15.76%	-16.21%	-	-	-	-
Molecular Diagnostic Vectra Testing	-	-	-	-	48.3M	39.1M	-	-	-	-
Molecular Diagnostic Vectra Testing Growth	-	-	-	-	-	-19.05%	-	-	-	-
Molecular Diagnostic Prolaris Testing	-	-	-	-	25.5M	24.7M	-	-	-	-
Molecular Diagnostic Prolaris Testing Growth	-	-	-	-	-	-3.14%	-	-	-	-
Molecular Diagnostic Other Testing	-	-	-	-	8M	14.4M	-	-	-	-
Molecular Diagnostic Other Testing Growth	-	-	-	-	-	80.00%	-	-	-	-
Molecular Diagnostic Endo Predict Testing	-	-	-	-	10.4M	10.5M	-	-	-	-
Molecular Diagnostic Endo Predict Testing Growth	-	-	-	-	-	0.96%	-	-	-	-
Diagnostics	695.5M	705.7M	722.1M	-	-	-	-	-	-	-
Diagnostics Growth	-	1.47%	2.32%	-	-	-	-	-	-	-
All Others	-	-	49.3M	-	-	-	-	-	-	-
All Others Growth	-	-	-	-	-	-	-	-	-	-
Others	27.6M	48.1M	-	-	-	-	-	-	-	-
Others Growth	-	74.28%	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	24.2M	84.5M	671.7M	769.5M
UNITED STATES Growth	-	-	-	-	-	-	-	249.17%	694.91%	14.56%
Non-US	-	-	-	-	-	-	40.5M	44.1M	81.5M	68.1M
Non-US Growth	-	-	-	-	-	-	-	8.89%	84.81%	-16.44%

Frequently Asked Questions

Growth & Financials

Myriad Genetics, Inc. (MYGN) reported $832.9M in revenue for fiscal year 2024. This represents a 68% increase from $496.0M in 2011.

Myriad Genetics, Inc. (MYGN) grew revenue by 11.2% over the past year. This is steady growth.

Myriad Genetics, Inc. (MYGN) reported a net loss of $395.2M for fiscal year 2024.

Dividend & Returns

Myriad Genetics, Inc. (MYGN) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.

Myriad Genetics, Inc. (MYGN) had negative free cash flow of $50.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Myriad Genetics, Inc. (MYGN) 10-Year Financial Performance & Capital Metrics

MYGN • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingHereditary & Pharmacogenomic Testing

Revenue $838M +11.2%
EBITDA -$62M +68.1%
Net Income -$127M +51.7%
EPS (Diluted) -1.41 +55.7%
Gross Margin 69.89% +1.8%
EBITDA Margin -7.44% +71.3%
Operating Margin -14.74% +56.9%
Net Margin -15.2% +56.5%
ROE -17.15% +45.6%
ROIC -12.01% +44.7%
Debt/Equity 0.20 +3.0%
Interest Coverage -44.11 +50.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.8x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.48%

5Y5.58%

3Y6.64%

TTM3.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-154.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM-136.52%

ROCE

10Y Avg-5.8%

5Y Avg-16.32%

3Y Avg-17.11%

Latest-13.32%

Peer Comparison

Hereditary & Pharmacogenomic Testing

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PREPrenetics Global Limited	226.73M	14.87	-4.09	40.83%	-93.53%	-33.01%		0.03
MYGNMyriad Genetics, Inc.	563.01M	6.04	-4.28	11.21%	-47.45%	-101.83%		0.20

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	753.8M	771.4M	772.6M	851.1M	638.6M	557M	690.6M	678.4M	753.2M	837.6M
Revenue Growth %	0.04%	0.02%	0%	0.1%	-0.25%	-0.13%	0.24%	-0.02%	0.11%	0.11%
Cost of Goods Sold+	157.3M	171.2M	177.2M	201M	186.1M	178.2M	197.6M	202M	236.2M	252.2M
COGS % of Revenue	0.21%	0.22%	0.23%	0.24%	0.29%	0.32%	0.29%	0.3%	0.31%	0.3%
Gross Profit+	596.5M	600.2M	595.4M	650.1M	452.5M	378.8M	493M	476.4M	517M	585.4M
Gross Margin %	0.79%	0.78%	0.77%	0.76%	0.71%	0.68%	0.71%	0.7%	0.69%	0.7%
Gross Profit Growth %	0.04%	0.01%	-0.01%	0.09%	-0.3%	-0.16%	0.3%	-0.03%	0.09%	0.13%
Operating Expenses+	429.7M	550.8M	537.9M	642.5M	684.2M	653.3M	683.5M	617M	774.4M	708.9M
OpEx % of Revenue	0.57%	0.71%	0.7%	0.75%	1.07%	1.17%	0.99%	0.91%	1.03%	0.85%
Selling, General & Admin	359.1M	476.4M	467.1M	556.6M	507.3M	500.7M	537.8M	514.7M	572.9M	560M
SG&A % of Revenue	0.48%	0.62%	0.6%	0.65%	0.79%	0.9%	0.78%	0.76%	0.76%	0.67%
Research & Development	70.6M	74.4M	70.8M	85.9M	77.2M	80.9M	81.9M	85.4M	88.7M	113.4M
R&D % of Revenue	0.09%	0.1%	0.09%	0.1%	0.12%	0.15%	0.12%	0.13%	0.12%	0.14%
Other Operating Expenses	1.2M	-2.5M	-400K	0	99.7M	0	63.8M	16.9M	112.8M	35.5M
Operating Income+	166.8M	49.4M	118.7M	7.6M	-231.7M	-194.8M	-190.5M	-140.6M	-257.4M	-123.5M
Operating Margin %	0.22%	0.06%	0.15%	0.01%	-0.36%	-0.35%	-0.28%	-0.21%	-0.34%	-0.15%
Operating Income Growth %	0.24%	-0.7%	1.4%	-0.94%	-31.49%	0.16%	0.02%	0.26%	-0.83%	0.52%
EBITDA+	193.5M	97.7M	173.1M	80.6M	-159.7M	-123.4M	-127.7M	-87.9M	-195.5M	-62.3M
EBITDA Margin %	0.26%	0.13%	0.22%	0.09%	-0.25%	-0.22%	-0.18%	-0.13%	-0.26%	-0.07%
EBITDA Growth %	0.22%	-0.5%	0.77%	-0.53%	-2.98%	0.23%	-0.03%	0.31%	-1.22%	0.68%
D&A (Non-Cash Add-back)	26.7M	48.3M	54.4M	73M	72M	71.4M	62.8M	52.7M	61.9M	61.2M
EBIT	166.8M	0	0	12M	-212.5M	-194.8M	-50.5M	-137.4M	-259.3M	-120.7M
Net Interest Income+	600K	-4.8M	-1.4M	-8.8M	-7.8M	9.2M	-5.9M	-600K	-400K	-1.1M
Interest Income	900K	1.2M	1.8M	3.2M	3M	9.2M	700K	2.6M	2.5M	1.7M
Interest Expense	300K	6M	3.2M	12M	10.8M	0	6.6M	3.2M	2.9M	2.8M
Other Income/Expense	1.2M	-1.7M	60.8M	-7.6M	8.4M	-88.9M	133.4M	0	-4.8M	0
Pretax Income+	168.9M	42.9M	116.9M	0	-223.3M	-283.7M	-57.1M	-140.6M	-262.2M	-123.5M
Pretax Margin %	0.22%	0.06%	0.15%	-	-0.35%	-0.51%	-0.08%	-0.21%	-0.35%	-0.15%
Income Tax+	43.6M	21.3M	-13.9M	-4.4M	-23.7M	59.9M	-29.9M	-28.6M	1.1M	3.8M
Effective Tax Rate %	0.74%	0.51%	1.12%	-	0.89%	0.79%	0.48%	0.8%	1%	1.03%
Net Income+	125.3M	21.8M	131M	4.6M	-199.5M	-223.7M	-27.2M	-112M	-263.3M	-127.3M
Net Margin %	0.17%	0.03%	0.17%	0.01%	-0.31%	-0.4%	-0.04%	-0.17%	-0.35%	-0.15%
Net Income Growth %	0.56%	-0.83%	5.01%	-0.96%	-44.37%	-0.12%	0.88%	-3.12%	-1.35%	0.52%
Net Income (Continuing)	125.3M	-	-	4.4M	-199.6M	-	-27.2M	-112M	-263.3M	-127.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	-400K	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.71	0.32	1.82	0.06	-2.69	-2.99	-0.35	-1.39	-3.18	-1.41
EPS Growth %	0.58%	-0.81%	4.69%	-0.97%	-45.36%	-0.11%	0.88%	-2.97%	-1.29%	0.56%
EPS (Basic)	1.79	0.32	1.89	0.06	-2.69	-2.99	-0.35	-1.39	-3.18	-1.41
Diluted Shares Outstanding	73.4M	68.8M	72M	76M	74.3M	74.78M	78M	80.6M	82.8M	90.6M
Basic Shares Outstanding	70M	68.3M	69.4M	73.5M	74.3M	74.7M	77.71M	80.58M	82.8M	90.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	314.5M	317.1M	326.4M	348.6M	348.6M	389.4M	484.8M	274.6M	313.6M	298M
Cash & Short-Term Investments	159M	150.7M	180.6M	136.9M	136.9M	150.7M	339.8M	114.9M	140.9M	102.4M
Cash Only	68.5M	102.4M	110.9M	93.2M	93.2M	117M	258.4M	56.9M	132.1M	102.4M
Short-Term Investments	90.5M	48.3M	69.7M	43.7M	43.7M	33.7M	81.4M	58M	8.8M	0
Accounts Receivable	95M	111.3M	102.1M	138.6M	138.6M	89.5M	91.3M	101.6M	114.3M	121.2M
Days Sales Outstanding	46	52.66	48.24	59.44	79.22	58.65	48.25	54.66	55.39	52.82
Inventory	38.3M	42.2M	34.3M	31.4M	31.4M	27.1M	15.3M	20.1M	22M	27.5M
Days Inventory Outstanding	88.87	89.97	70.65	57.02	61.59	55.51	28.26	36.32	34	39.8
Other Current Assets	22.2M	12.9M	9.4M	46.4M	41.7M	0	38.4M	20.4M	19.4M	30.5M
Total Non-Current Assets+	566M	907.3M	847.7M	1.21B	1.21B	1.03B	835.9M	924.1M	832.9M	729.6M
Property, Plant & Equipment	58.3M	51.1M	43.2M	57.3M	57.3M	100.4M	125.3M	187.3M	180.6M	172.4M
Fixed Asset Turnover	12.93x	15.10x	17.88x	14.85x	11.14x	5.55x	5.51x	3.62x	4.17x	4.86x
Goodwill	195.3M	316.1M	318.6M	417.2M	417.2M	329.2M	239.2M	286.8M	287.4M	286.3M
Intangible Assets	227.5M	491.6M	455.2M	684.7M	684.7M	578.8M	404.1M	379.7M	349.5M	262.4M
Long-Term Investments	79.9M	48.5M	30.7M	54.9M	54.9M	21M	59M	54.8M	0	0
Other Non-Current Assets	5M	0	0	-1.21B	0	0	8.3M	15.5M	15.4M	8.5M
Total Assets+	880.5M	1.22B	1.17B	1.56B	1.56B	1.42B	1.32B	1.2B	1.15B	1.03B
Asset Turnover	0.86x	0.63x	0.66x	0.54x	0.41x	0.39x	0.52x	0.57x	0.66x	0.82x
Asset Growth %	0.15%	0.39%	-0.04%	0.33%	0%	-0.09%	-0.07%	-0.09%	-0.04%	-0.1%
Total Current Liabilities+	72.3M	217.5M	102.2M	117.8M	117.8M	145.9M	204.3M	137.2M	155.9M	164.1M
Accounts Payable	21.1M	22M	26M	33.3M	33.3M	20.5M	29.6M	28.8M	25.8M	32.3M
Days Payables Outstanding	48.96	46.9	53.56	60.47	65.31	41.99	54.68	52.04	39.87	46.75
Short-Term Debt	0	65.6M	68.3M	78.9M	78.9M	0	13M	14.1M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	1000K	600K	0	0
Other Current Liabilities	49.5M	127.3M	5.3M	82.3M	-29.9M	49.7M	126.9M	64.9M	38.2M	64.9M
Current Ratio	4.35x	1.46x	3.19x	2.96x	2.96x	2.67x	2.37x	2.00x	2.01x	1.82x
Quick Ratio	3.82x	1.26x	2.86x	2.69x	2.69x	2.48x	2.30x	1.85x	1.87x	1.65x
Cash Conversion Cycle	85.91	95.73	65.33	55.99	75.49	72.17	21.84	38.94	49.52	45.87
Total Non-Current Liabilities+	60.1M	229.1M	107M	356M	356M	391.9M	148.6M	175.7M	207.4M	162.4M
Long-Term Debt	0	99.1M	9.3M	233.5M	233.5M	224.8M	79.3M	130.9M	38.5M	39.6M
Capital Lease Obligations	0	0	0	0	0	50.6M	0	0	97.4M	87.9M
Deferred Tax Liabilities	17.9M	84.4M	57.3M	82.6M	82.6M	0	35.8M	3.5M	0	0
Other Non-Current Liabilities	42.2M	45.6M	40.4M	39.9M	39.9M	116.5M	33.5M	41.3M	71.5M	34.9M
Total Liabilities	132.4M	446.6M	209.2M	473.8M	473.8M	537.8M	352.9M	312.9M	363.3M	326.5M
Total Debt+	0	99.1M	9.3M	233.5M	233.5M	289M	92.3M	145M	152.1M	140.3M
Net Debt	-68.5M	-3.3M	-101.6M	140.3M	140.3M	172M	-166.1M	88.1M	20M	37.9M
Debt / Equity	-	0.13x	0.01x	0.21x	0.21x	0.33x	0.10x	0.16x	0.19x	0.20x
Debt / EBITDA	-	1.01x	0.05x	2.90x	-	-	-	-	-	-
Net Debt / EBITDA	-0.35x	-0.03x	-0.59x	1.74x	-	-	-	-	-	-
Interest Coverage	556.00x	8.23x	37.09x	0.63x	-21.45x	-	-28.86x	-43.94x	-88.76x	-44.11x
Total Equity+	748.1M	777.8M	964.9M	1.09B	1.09B	881M	967.8M	885.8M	783.2M	701.1M
Equity Growth %	0.13%	0.04%	0.24%	0.13%	0%	-0.19%	0.1%	-0.08%	-0.12%	-0.1%
Book Value per Share	10.19	11.31	13.40	14.33	14.66	11.78	12.41	10.99	9.46	7.74
Total Shareholders' Equity	748.1M	778.2M	964.9M	1.09B	1.09B	881M	967.8M	885.8M	783.2M	701.1M
Common Stock	700K	700K	700K	700K	700K	800K	800K	800K	900K	900K
Retained Earnings	-73.2M	-68.4M	52.8M	25.6M	25.6M	-227M	-254.2M	-366.2M	-629.5M	-756.8M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-9.5M	-5.5M	-4M	-5.4M	-5.4M	-2.3M	-5.1M	-8.9M	-3.7M	-800K
Minority Interest	0	-400K	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	166.3M	106.2M	115.9M	83.7M	60.7M	-26.9M	18.6M	-106.3M	-110.9M	-8.7M
Operating CF Margin %	0.22%	0.14%	0.15%	0.1%	0.1%	-0.05%	0.03%	-0.16%	-0.15%	-0.01%
Operating CF Growth %	0.18%	-0.36%	0.09%	-0.28%	-0.27%	-1.44%	1.69%	-6.72%	-0.04%	0.92%
Net Income	117.2M	17.4M	133.3M	4.6M	-199.5M	-223.7M	-27.2M	-112M	-263.3M	-127.3M
Depreciation & Amortization	26.8M	48.3M	54.4M	73M	72M	71.4M	62.8M	52.7M	61.9M	61.2M
Stock-Based Compensation	31.6M	29.9M	27.1M	33.5M	25.2M	24.3M	36.3M	38.1M	40.7M	49.8M
Deferred Taxes	10.8M	2M	-23.8M	13.1M	-54.1M	-54.5M	-34.7M	-31.9M	-600K	-300K
Other Non-Cash Items	32.4M	3M	-83.6M	-1.1M	99.2M	70.9M	-139.4M	30.3M	23.4M	62.3M
Working Capital Changes	-52.5M	5.6M	8.5M	-39.4M	117.9M	30.2M	120.8M	-83.5M	27M	-54.4M
Change in Receivables	-26.8M	-3.5M	-8M	-18.2M	64M	28.9M	-8.8M	7.7M	3.8M	-8.7M
Change in Inventory	-14.6M	-1.2M	7.9M	8M	1.6M	1.3M	1.6M	-2.9M	-1.8M	-6.2M
Change in Payables	0	-3M	4M	1.1M	-10.7M	0	9.2M	-3.5M	-3.7M	4.7M
Cash from Investing+	-91.4M	-146.3M	-11.6M	-286.4M	19.3M	61.6M	274.4M	-77.5M	31.9M	-11.9M
Capital Expenditures	-5M	-6.1M	-8.4M	-8.6M	-10.2M	-13.2M	-18M	-45.3M	-73.3M	-29.7M
CapEx % of Revenue	0.01%	0.01%	0.01%	0.01%	0.02%	0.02%	0.03%	0.07%	0.1%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	74.8M	0	0	0	0
Cash from Financing+	-68.3M	71.8M	-95M	182.3M	-10M	-1M	-150.6M	-8M	152.9M	-7.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	94.3M	5.4M	-5M	7.3M	-1.4M	11.5M	75.8M	-8M	-4.5M	-7.5M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	161.3M	100.1M	107.5M	75.1M	50.5M	-40.1M	600K	-151.6M	-184.2M	-38.4M
FCF Margin %	0.21%	0.13%	0.14%	0.09%	0.08%	-0.07%	0%	-0.22%	-0.24%	-0.05%
FCF Growth %	0.38%	-0.38%	0.07%	-0.3%	-0.33%	-1.79%	1.01%	-253.67%	-0.22%	0.79%
FCF per Share	2.20	1.45	1.49	0.99	0.68	-0.54	0.01	-1.88	-2.22	-0.42
FCF Conversion (FCF/Net Income)	1.33x	4.87x	0.88x	18.20x	-0.30x	0.12x	-0.68x	0.95x	0.42x	0.07x
Interest Paid	300K	5.6M	3M	11.6M	9.5M	-	4.4M	-	1.4M	1.9M
Taxes Paid	32M	12.3M	11.7M	6.5M	1M	-	4.6M	1.8M	1.9M	2.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	17.77%	2.86%	15.03%	0.45%	-18.32%	-22.71%	-2.94%	-12.08%	-31.55%	-17.15%
Return on Invested Capital (ROIC)	19.58%	5.1%	10.87%	0.54%	-14.14%	-12.8%	-15.41%	-11.88%	-21.73%	-12.01%
Gross Margin	79.13%	77.81%	77.06%	76.38%	70.86%	68.01%	71.39%	70.22%	68.64%	69.89%
Net Margin	16.62%	2.83%	16.96%	0.54%	-31.24%	-40.16%	-3.94%	-16.51%	-34.96%	-15.2%
Debt / Equity	-	0.13x	0.01x	0.21x	0.21x	0.33x	0.10x	0.16x	0.19x	0.20x
Interest Coverage	556.00x	8.23x	37.09x	0.63x	-21.45x	-	-28.86x	-43.94x	-88.76x	-44.11x
FCF Conversion	1.33x	4.87x	0.88x	18.20x	-0.30x	0.12x	-0.68x	0.95x	0.42x	0.07x
Revenue Growth	4.25%	2.33%	0.16%	10.16%	-24.97%	-12.78%	23.99%	-1.77%	11.03%	11.21%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2021	2022	2023	2024
Testing Revenue	-	-	-	-	-	-	-	-	753.2M	-
Testing Revenue Growth	-	-	-	-	-	-	-	-	-	-
Molecular Diagnostic Testing	-	-	-	719.3M	789.4M	586.9M	-	-	-	-
Molecular Diagnostic Testing Growth	-	-	-	-	9.75%	-25.65%	-	-	-	-
Molecular Diagnostic Hereditary Cancer Testing	-	-	-	-	479.7M	347.4M	-	-	-	-
Molecular Diagnostic Hereditary Cancer Testing Growth	-	-	-	-	-	-27.58%	-	-	-	-
Molecular Diagnostic Prenatal Testing	-	-	-	-	104.9M	76.7M	-	-	-	-
Molecular Diagnostic Prenatal Testing Growth	-	-	-	-	-	-26.88%	-	-	-	-
Molecular Diagnostic Genesight Testing	-	-	-	-	112.6M	74.1M	-	-	-	-
Molecular Diagnostic Genesight Testing Growth	-	-	-	-	-	-34.19%	-	-	-	-
Pharmaceutical And Clinical Services	-	-	-	53.3M	61.7M	51.7M	-	-	-	-
Pharmaceutical And Clinical Services Growth	-	-	-	-	15.76%	-16.21%	-	-	-	-
Molecular Diagnostic Vectra Testing	-	-	-	-	48.3M	39.1M	-	-	-	-
Molecular Diagnostic Vectra Testing Growth	-	-	-	-	-	-19.05%	-	-	-	-
Molecular Diagnostic Prolaris Testing	-	-	-	-	25.5M	24.7M	-	-	-	-
Molecular Diagnostic Prolaris Testing Growth	-	-	-	-	-	-3.14%	-	-	-	-
Molecular Diagnostic Other Testing	-	-	-	-	8M	14.4M	-	-	-	-
Molecular Diagnostic Other Testing Growth	-	-	-	-	-	80.00%	-	-	-	-
Molecular Diagnostic Endo Predict Testing	-	-	-	-	10.4M	10.5M	-	-	-	-
Molecular Diagnostic Endo Predict Testing Growth	-	-	-	-	-	0.96%	-	-	-	-
Diagnostics	695.5M	705.7M	722.1M	-	-	-	-	-	-	-
Diagnostics Growth	-	1.47%	2.32%	-	-	-	-	-	-	-
All Others	-	-	49.3M	-	-	-	-	-	-	-
All Others Growth	-	-	-	-	-	-	-	-	-	-
Others	27.6M	48.1M	-	-	-	-	-	-	-	-
Others Growth	-	74.28%	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	24.2M	84.5M	671.7M	769.5M
UNITED STATES Growth	-	-	-	-	-	-	-	249.17%	694.91%	14.56%
Non-US	-	-	-	-	-	-	40.5M	44.1M	81.5M	68.1M
Non-US Growth	-	-	-	-	-	-	-	8.89%	84.81%	-16.44%

Frequently Asked Questions

Growth & Financials

Myriad Genetics, Inc. (MYGN) reported $832.9M in revenue for fiscal year 2024. This represents a 68% increase from $496.0M in 2011.

Myriad Genetics, Inc. (MYGN) grew revenue by 11.2% over the past year. This is steady growth.

Myriad Genetics, Inc. (MYGN) reported a net loss of $395.2M for fiscal year 2024.

Dividend & Returns

Myriad Genetics, Inc. (MYGN) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.

Myriad Genetics, Inc. (MYGN) had negative free cash flow of $50.0M in fiscal year 2024, likely due to heavy capital investments.